167 related articles for article (PubMed ID: 30018046)
1. Mechanisms by Which Dendritic Cells Present Tumor Microparticle Antigens to CD8
Ma J; Wei K; Zhang H; Tang K; Li F; Zhang T; Liu J; Xu P; Yu Y; Sun W; Zhu L; Chen J; Zhou L; Liang X; Lv J; Fiskesund R; Liu Y; Huang B
Cancer Immunol Res; 2018 Sep; 6(9):1057-1068. PubMed ID: 30018046
[TBL] [Abstract][Full Text] [Related]
2. Cell-free tumor microparticle vaccines stimulate dendritic cells via cGAS/STING signaling.
Zhang H; Tang K; Zhang Y; Ma R; Ma J; Li Y; Luo S; Liang X; Ji T; Gu Z; Lu J; He W; Cao X; Wan Y; Huang B
Cancer Immunol Res; 2015 Feb; 3(2):196-205. PubMed ID: 25477253
[TBL] [Abstract][Full Text] [Related]
3. Molecular and cellular requirements for enhanced antigen cross-presentation to CD8 cytotoxic T lymphocytes.
Oizumi S; Strbo N; Pahwa S; Deyev V; Podack ER
J Immunol; 2007 Aug; 179(4):2310-7. PubMed ID: 17675492
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines.
Dolan BP; Gibbs KD; Ostrand-Rosenberg S
J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172
[TBL] [Abstract][Full Text] [Related]
5. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
6. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma.
Goldszmid RS; Idoyaga J; Bravo AI; Steinman R; Mordoh J; Wainstok R
J Immunol; 2003 Dec; 171(11):5940-7. PubMed ID: 14634105
[TBL] [Abstract][Full Text] [Related]
8. Enhanced suppression of polyclonal CD8
Mu C; Zhang X; Wang L; Xu A; Ahmed KA; Pang X; Chibbar R; Freywald A; Huang J; Zhu Y; Xiang J
J Leukoc Biol; 2017 May; 101(5):1221-1231. PubMed ID: 28096300
[TBL] [Abstract][Full Text] [Related]
9. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
[TBL] [Abstract][Full Text] [Related]
10. Tumor-Derived Microvesicles Enhance Cross-Processing Ability of Clinical Grade Dendritic Cells.
Dionisi M; De Archangelis C; Battisti F; Rahimi Koshkaki H; Belleudi F; Zizzari IG; Ruscito I; Albano C; Di Filippo A; Torrisi MR; Benedetti Panici P; Napoletano C; Nuti M; Rughetti A
Front Immunol; 2018; 9():2481. PubMed ID: 30455687
[TBL] [Abstract][Full Text] [Related]
11. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
[TBL] [Abstract][Full Text] [Related]
12. Self-adjuvanted nanovaccine for cancer immunotherapy: Role of lysosomal rupture-induced ROS in MHC class I antigen presentation.
Wang C; Li P; Liu L; Pan H; Li H; Cai L; Ma Y
Biomaterials; 2016 Feb; 79():88-100. PubMed ID: 26702587
[TBL] [Abstract][Full Text] [Related]
13. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
Wiethe C; Dittmar K; Doan T; Lindenmaier W; Tindle R
J Immunol; 2003 Mar; 170(6):2912-22. PubMed ID: 12626542
[TBL] [Abstract][Full Text] [Related]
14. A novel strategy utilizing ultrasound for antigen delivery in dendritic cell-based cancer immunotherapy.
Suzuki R; Oda Y; Utoguchi N; Namai E; Taira Y; Okada N; Kadowaki N; Kodama T; Tachibana K; Maruyama K
J Control Release; 2009 Feb; 133(3):198-205. PubMed ID: 19000727
[TBL] [Abstract][Full Text] [Related]
15. Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide.
Ikeuchi N; Futami J; Hosoi A; Noji S; Kurachi M; Ueha S; Fujii S; Yamada H; Matsushima K; Moriyasu F; Kakimi K
Biochem Biophys Res Commun; 2010 Feb; 392(2):217-22. PubMed ID: 20067764
[TBL] [Abstract][Full Text] [Related]
16. Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model.
Powell KL; Stephens AS; Ralph SJ
Cancer Immunol Immunother; 2015 Jul; 64(7):861-72. PubMed ID: 25893808
[TBL] [Abstract][Full Text] [Related]
17. Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.
Chiang CY; Chen YJ; Wu CC; Liu SJ; Leng CH; Chen HW
Front Immunol; 2018; 9():822. PubMed ID: 29755461
[TBL] [Abstract][Full Text] [Related]
18. CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells.
Hu HM; Winter H; Ma J; Croft M; Urba WJ; Fox BA
J Immunol; 2002 Nov; 169(9):4897-904. PubMed ID: 12391201
[TBL] [Abstract][Full Text] [Related]
19. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
20. A Brucella spp. Protease Inhibitor Limits Antigen Lysosomal Proteolysis, Increases Cross-Presentation, and Enhances CD8+ T Cell Responses.
Coria LM; Ibañez AE; Tkach M; Sabbione F; Bruno L; Carabajal MV; Berguer PM; Barrionuevo P; Schillaci R; Trevani AS; Giambartolomei GH; Pasquevich KA; Cassataro J
J Immunol; 2016 May; 196(10):4014-29. PubMed ID: 27084100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]